What is HC Wainwright’s Estimate for Genelux Q1 Earnings?

Genelux Co. (NASDAQ:GNLX) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Genelux in a research note issued on Tuesday, March 25th. HC Wainwright analyst E. Bodnar anticipates that the company will earn ($0.16) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Genelux’s Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.22) EPS and FY2029 earnings at $2.58 EPS.

Genelux Trading Down 5.9 %

Genelux stock opened at $3.20 on Wednesday. Genelux has a 12 month low of $1.60 and a 12 month high of $6.50. The company has a market capitalization of $110.52 million, a price-to-earnings ratio of -3.37 and a beta of -1.41. The business’s fifty day simple moving average is $4.03 and its two-hundred day simple moving average is $3.09.

Hedge Funds Weigh In On Genelux

Several large investors have recently modified their holdings of GNLX. Brown Brothers Harriman & Co. increased its stake in Genelux by 76.2% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 21,075 shares of the company’s stock valued at $50,000 after purchasing an additional 9,114 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Genelux during the third quarter valued at approximately $59,000. Geode Capital Management LLC increased its position in shares of Genelux by 39.7% during the third quarter. Geode Capital Management LLC now owns 316,160 shares of the company’s stock valued at $749,000 after acquiring an additional 89,854 shares in the last quarter. Apollon Wealth Management LLC raised its holdings in Genelux by 20.4% in the 4th quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock worth $40,000 after acquiring an additional 2,857 shares during the last quarter. Finally, D.A. Davidson & CO. bought a new position in Genelux in the 4th quarter valued at approximately $51,000. Hedge funds and other institutional investors own 37.33% of the company’s stock.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.